



RARE DISEASES + ORPHAN PRODUCTS

Breakthrough Summit

Washington, DC

OCT
20-22
2024

Call for Abstracts

Academics, researchers, industry, government agencies, healthcare professionals, patient organizations, and other interested parties, such as students that have conducted rare disease or orphan product research studies or public health projects relevant in rare disease are invited to submit an abstract for inclusion in the poster hall at the **National Organization for Rare Disorders'** Rare Disease and Orphan Products Breakthrough Summit taking place **October 20-22, 2024**.

The NORD Breakthrough Summit Abstract Review Committee is interested in abstracts that highlight new research, change clinical practice, enhance patient care, address disparities in health or increase patient engagement or patient advocacy. The five (5) categories listed below are the focus areas for the event. Please use these as a guide as you develop your abstract for consideration of inclusion in the NORD Breakthrough Summit Poster Hall.

Categories

1. Innovative Research in Rare Diseases and Orphan Products

Abstracts may cover any type of innovative rare disease or orphan products research, including preclinical models, clinical studies, case studies, patient-focused studies, technological, economic, or policy research as it relates to health and social issues. Also included in this theme are collaborative initiatives and centers of excellence that involve ground-breaking strategies or projects that could be useful to other groups, organizations, patients, government, academics or professionals in the rare disease and orphan product community.

2. Medical Education Advancement in Rare Diseases and Orphan Products

Abstracts should cover public health awareness and education of healthcare professionals (HCPs); information exchange or training that leads to advancements in screening and/or diagnosis; or innovative models for medical education training.

3. Patient Community Building in Rare Diseases

Abstracts in this theme should cover topics such as advancements in patient education; novel ways to increase patient engagement in the rare disease community; or successful

models in increasing patient advocacy and awareness by leveraging technology or communications channels.

4. Health Equity in Rare Diseases

Abstracts in this category should include research or programming to address disparities in health as it relates to outcomes, access, and care for those living with rare diseases, particularly those from historically marginalized communities.

5. Other Topics

These abstracts should still relate to the overall topic of rare diseases and orphan products but do not fit within the themes previously listed.

Eligibility

You may submit poster abstracts under one of the two submission groupings below:

1. Student (graduate or undergraduate)

Individuals submitting an abstract under the Student category must be an undergraduate or graduate student enrolled in a Bachelor's, Master's, PharmD, MD, DVM, or PhD (or equivalent) academic program at an accredited academic institution. *Individuals must be able to provide documentation of this enrollment upon request.*

The submitted research must have been conducted at an academic institution. Individuals who completed a degree during the 2024 academic year may submit a student poster only if they are able to provide documentation that they were an eligible student at the time the research was conducted.

2. Professional (post-doctoral scholars, medical residents/fellows/professionals, patient advocates/advocacy groups, government agencies and manufacturers.)

All poster abstracts must be noncommercial and without inclusion of trade names or logo by any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Any mention of specific products or and/or services must be limited to generic names, with no inclusion of trade names in any area of the poster, including poster titles.

Key Dates

Submission deadline via submission form	June 12, 2024
NORD notifies authors of acceptance on this date	July 23, 2024
Registration deadline for accepted Abstract attendees	September 1, 2024
Deadline for Digital posters for Accepted Abstracts Attendees. <small>Digital posters sent after this date are not guaranteed to be included on the event app</small>	September 26, 2024
Accepted Attendees set up Posters in Poster Hall	October 20, 2024

General Requirements & Guidelines

1. All abstracts must be submitted by June 12, 2024, with no exceptions. Abstracts will only be accepted via this [form](#).
2. Abstracts should be noncommercial. Generic names of drugs should be used throughout the abstract.
3. Posters should include data for consideration. Preliminary and pilot data will be accepted.
4. Abstracts should be original in research, include appropriate empirical evidence, and not have been widely presented or circulated prior to the NORD Summit.
5. Encore abstracts are welcome if the work does not infringe upon any copyright, proprietary or personal right of any third party and so long as the data has been updated.
6. Copyright issues: Authors who use resources that are not their own (pictures, charts, graphs, etc.) in their abstract must cite the original source. If authors draw heavily on another source, it is the author(s)'s responsibility to seek and receive permission to use the material.
7. Use of data accepted and/or published as a journal article: Data accepted or published by a medical or academic journal may be used if it is cited and does not infringe on any copyright issues with the journal. It is the author(s)' responsibility to seek and receive permission to use the data.
8. Referral to webpages or URLs may not be used in the abstract.
9. Author(s) may not submit the same abstract under more than one category. Duplicate submissions will not be accepted.
10. Author(s) may not present more than three abstracts during the NORD Summit, and each abstract must be different.
11. Submission of an abstract constitutes a commitment by the presenting author to present their work in-person at the NORD Breakthrough Summit Poster Hall if the abstract is accepted

12. Accepted abstracts may be shared on the NORD website for 2 years.
13. NORD does not assign nor retain copyright on posters submitted for the NORD Breakthrough Summit. Therefore, any permissions to reuse materials after the NORD Breakthrough Summit should be approved by the authors directly.

Format

Abstracts should be **no more than one page**, excluding space for tables and figures, and utilize the following specifications:

- Minimum font size 11
- Single-spaced rows
- One-inch margins

Abstracts submitted with a length of longer than one page will not be reviewed and considered for inclusion in the NORD Summit poster hall.

The following content is required:

- **Title of Abstract**
- **Authors, Institution, and Institution Location** (City, State or Province, and Country)
 - Provide all authors' names in the order in which they should be listed.
 - Presenting author to be designated prior to submission
- **Purpose:** Rationale of the study and/or the question addressed
- **Background:** Brief context around your study topic and why it is important
- **Methods:** Experimental approach, materials, and methods used in the study
- **Results:** Data and results obtained in the study
- **Conclusions:** Conclusions and/or implications of the results

Notification

Abstracts will be evaluated by the 2024 NORD Breakthrough Summit Abstract Review Committee. The main contact for each abstract will be notified by NORD staff about acceptance or nonacceptance **on July 23, 2024**. If an abstract is accepted, the main contact will be provided with additional information about the poster presentation format and requirements.

5 selected abstracts will be chosen by the review committee for Lightning Round oral presentations at the 2024 NORD Breakthrough Summit. This will allow the author 5 minutes

on our main stage to share key findings of their research with our audience.

The submission of an abstract constitutes a commitment by the presenting author to present their work in the poster hall if the abstract is accepted. All additional abstract authors are encouraged to purchase a registration to attend the Summit. If the original designated presenting author is unable to attend, a co-author may be designated as an alternate presenter.